Preprint Article Version 1 This version not peer reviewed

The Application of Non-Invasive Apoptosis Detection Sensor (IADS) on Histone Deacetylation Inhibitors (HDACi) Induced Breast Cancer Cell Death

Version 1 : Received: 1 December 2017 / Approved: 1 December 2017 / Online: 1 December 2017 (12:08:13 CET)

A peer-reviewed article of this Preprint also exists.

Hsu, K.-W.; Huang, C.-Y.; Tam, K.-W.; Lin, C.-Y.; Huang, L.-C.; Lin, C.-L.; Hsieh, W.-S.; Chi, W.-M.; Chang, Y.-J.; Wei, P.-L.; Chen, S.-T.; Lee, C.-H. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death. Int. J. Mol. Sci. 2018, 19, 452. Hsu, K.-W.; Huang, C.-Y.; Tam, K.-W.; Lin, C.-Y.; Huang, L.-C.; Lin, C.-L.; Hsieh, W.-S.; Chi, W.-M.; Chang, Y.-J.; Wei, P.-L.; Chen, S.-T.; Lee, C.-H. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death. Int. J. Mol. Sci. 2018, 19, 452.

Journal reference: Int. J. Mol. Sci. 2018, 19, 452
DOI: 10.3390/ijms19020452

Abstract

Breast cancer is the most common malignancies in women and the second leading cause of cancer death in women. Triple negative breast cancer (TNBC) subtype is a breast cancer subset without ER, PR and HER2 expression, limiting treatment options and presenting a poorer survival rate. Thus, we investigated whether HDACi would be used as potential anti-cancer therapy on breast cancer cells. In this study, we found TNBC and HER2-enrich breast cancers are extremely sensitive to Panobinostat, Belinostat of HDACi via experiments of cell viability assay, apoptotic marker identification and flow cytometry measurement. On the other hand, we developed a bioluminescence based live cell non-invasive apoptosis detection sensor (IADS) detection system to evaluate the quantitative and kinetic analyses of apoptotic cell death by HDAC treatment on breast cancer cells. In addition, the use of HDACi may also be accompanied with chemotherapeutic agent such as doxorubicin to synergic drug sensitivity on TNBC cell (MDA-MB-231), but not in breast normal epithelia cells (MCF-10A), providing therapeutic benefits against breast tumor in clinic.

Subject Areas

non-invasive apoptosis detection sensor; breast cancer; HDACi

Readers' Comments and Ratings (0)

Leave a public comment
Send a private comment to the author(s)
Rate this article
Views 0
Downloads 0
Comments 0
Metrics 0
Leave a public comment

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.